Zydus Wellness Q4 FY26 sales jump 62.6% YoY

Key update: standalone March 2026 numbers

Zydus Wellness reported a sharp improvement in its standalone March 2026 quarter, led by higher sales and operating profit. Standalone net sales for March 2026 stood at ₹132.6 crore, up 71.1% year-on-year from ₹77.5 crore in March 2025. Quarterly net profit rose to ₹13.3 crore, up 182.98% from ₹4.7 crore a year earlier.

EBITDA for the quarter was ₹24.6 crore, up 167.39% from ₹9.2 crore in March 2025. The company’s EPS for March 2026 was reported at ₹0.42 versus ₹0.74 in March 2025. Alongside these results, the dataset also provides a quarterly snapshot of standalone operations, including net sales, total expenditure, and operating profit across Mar 2025 to Mar 2026.

Consolidated Q4 FY26: revenue expands, PAT softens YoY

On a consolidated basis, revenue from operations in Q4 FY26 (March 2026 quarter) was ₹1,484.7 crore. This marked a 62.60% year-on-year increase versus ₹913.1 crore in Q4 FY25 and a 53.87% sequential rise from ₹964.9 crore in Q3 FY26. Total income for Q4 FY26 was ₹1,485.9 crore, compared with ₹913.9 crore in Q4 FY25 and ₹965.7 crore in Q3 FY26.

Profit before tax (after exceptional items) was ₹177.3 crore in Q4 FY26, compared with a loss of ₹41.5 crore in Q3 FY26 and ₹173.4 crore in Q4 FY25. Profit after tax came in at ₹162.0 crore in Q4 FY26, recovering from a loss of ₹39.9 crore in Q3 FY26, but down 5.76% from ₹171.9 crore in Q4 FY25.

FY26 consolidated performance: annual report metrics

In its integrated annual report for FY 2025-26, Zydus Wellness reported consolidated revenue from operations of ₹3,961.0 crore, up 46.2% year-on-year. Net profit for FY26 was reported at ₹197.2 crore. The report attributed the FY26 consolidated revenue growth primarily to the landmark acquisition of UK-based Comfort Click Limited (CCL) for GBP 242 million.

The annual report table in the dataset also lists net sales (₹ million) at 39,400 for FY26 and 26,912 for FY25, which corresponds to ₹3,940.0 crore and ₹2,691.2 crore respectively. Revenue from operations is listed at ₹3,961.0 crore for FY26 versus ₹2,708.9 crore for FY25.

What changed across domestic and international business

The FY26 filing notes that domestic business grew 2.4%, while the international business including the Comfort Click business delivered a like-to-like growth of 29.5%. The company also reported that gross margins improved by 772 basis points in FY 2025-26, with a cumulative recovery of 940 basis points over FY 2024-25 and FY 2025-26.

At the same time, the filing flags weakness in seasonal brands. Seasonal brands including Nycil and Glucon-D saw a revenue decline of 18.8% in FY26.

Standalone: quarterly run-rate and cost line items

The standalone March 2026 quarter is also presented with a break-up of operating income. Net sales or income from operations was ₹111.4 crore in Mar 2026, while other operating income was ₹21.2 crore, taking total income from operations to ₹132.6 crore. For comparison, total income from operations was ₹152.6 crore in Dec 2025 and ₹77.5 crore in Mar 2025.

On the cost side for Mar 2026, consumption of raw materials was ₹83.1 crore, employee cost was ₹14.3 crore, and depreciation was ₹6.3 crore. A separate quarterly table in the dataset shows total expenditure at ₹112.8 crore in Mar 2026, and operating profit at ₹19.8 crore.

Consolidated and standalone: key figures at a glance

Stock snapshot: price, range, and returns cited

The dataset lists Zydus Wellness on BSE (531335) and NSE (ZYDUSWELL). On BSE, the stock was shown at ₹584.55, down ₹13.75 or 2.30% at 01:17 PM. The day’s high was ₹606.55 and the day’s low was ₹548.55. The 52-week high is listed at ₹600 and the 52-week low at ₹357.55.

A separate Q&A line in the dataset states the current share price as ₹594.4. It also states that Zydus Wellness has a market capitalisation of ₹18,911.4731968 crore based on its latest share price. Another line notes the shares closed at ₹495.65 on May 15, 2026 (NSE) and delivered returns of 9.66% over the last six months and 35.23% over the last 12 months.

Upcoming corporate event: Q1 FY27 results date

The dataset lists “Quick Details” showing a results date of August 04, 2026 for Q1 FY 2026-2027. It adds that the board will consider the Q1 FY27 unaudited financial results on August 04, 2026. The same block lists the previous quarter revenue at ₹1,476.1 crore, previous quarter PAT at ₹162.0 crore, and previous quarter EBITDA margin at 18.2%.

Why these numbers matter for investors

The March 2026 standalone print shows a large year-on-year jump in sales, EBITDA, and profit, alongside a reported decline in EPS from ₹0.74 to ₹0.42. On the consolidated side, FY26 growth is presented as acquisition-led, with Comfort Click highlighted as a primary driver and international like-to-like growth of 29.5% cited in the annual report.

At the same time, the data also points to divergent performance within the portfolio, with seasonal brands like Nycil and Glucon-D seeing an 18.8% revenue decline in FY26. For market participants tracking the business mix, the combination of acquisition-driven international scale-up, margin recovery (772 bps in FY26), and category-specific pressure provides important context ahead of the next results cycle.

Conclusion

Zydus Wellness reported strong consolidated revenue expansion in FY26 and a sharp year-on-year jump in standalone March 2026 profits, with the Comfort Click acquisition repeatedly cited as a key factor behind the scale-up. The next near-term trigger on the calendar is the board meeting on August 04, 2026 to consider Q1 FY27 unaudited results.